Hepatic myofibroblasts are activated in response to chronic liver injury of any etiology to produce a fibrous scar. Despite extensive studies, the origin of myofibroblasts in different types of fibrotic liver diseases is unresolved. To identify distinct populations of myofibroblasts and quantify their contribution to hepatic fibrosis of two different etiologies, collagen-α1(I)-GFP mice were subjected to hepatotoxic (carbon tetrachloride; CCl 4 ) or cholestatic (bile duct ligation; BDL) liver injury. All myofibroblasts were purified by flow cytometry of GFP + cells and then different subsets identified by phenotyping. Liver resident activated hepatic stellate cells (aHSCs) and activated portal fibroblasts (aPFs) are the major source (>95%) of fibrogenic myofibroblasts in these models of liver fibrosis in mice. As previously reported using other methodologies, hepatic stellate cells (HSCs) are the major source of myofibroblasts (>87%) in CCl 4 liver injury. However, aPFs are a major source of myofibroblasts in cholestatic liver injury, contributing >70% of myofibroblasts at the onset of injury (5 d BDL). The relative contribution of aPFs decreases with progressive injury, as HSCs become activated and contribute to the myofibroblast population (14 and 20 d BDL). Unlike aHSCs, aPFs respond to stimulation with taurocholic acid and IL-25 by induction of collagen-α1(I) and IL-13, respectively. Furthermore, BDL-activated PFs express high levels of collagen type I and provide stimulatory signals to HSCs. Gene expression analysis identified several novel markers of aPFs, including a mesothelial-specific marker mesothelin. PFs may play a critical role in the pathogenesis of cholestatic liver fibrosis and, therefore, serve as an attractive target for antifibrotic therapy.
ECM deposition | markers of fibrogenic myofibroblasts C hronic liver injury of many etiologies results in liver fibrosis. There are two general types of chronic liver diseases, hepatocellular (injury to hepatocytes, such as chronic viral hepatitis and nonalcoholic steatohepatitis) and cholestatic (obstruction to bile flow, such as primary biliary cirrhosis and primary sclerosing cholangitis) (1) . Experimental rodent models of liver fibrosis mimic these two types of chronic liver injuries: Repeated carbon tetrachloride (CCl 4 ) administration produces hepatocelluar injury, and common bile duct ligation (BDL) produces cholestatic injury (2) . In all chronic liver diseases, myofibroblasts are embedded in the fibrous scar and are the source of this excessive extracellular matrix (ECM). Myofibroblasts, which are not present in normal liver, are characterized by distinct morphology, contractility with intracellular stress fibers [α-smooth muscle actin (α-SMA), nonmuscle myosin, and vimentin], and secretion of extracellular matrix (fibronectin and fibrillar collagens) (1, 2) .
The cells of origin of hepatic myofibroblasts are unresolved, and perhaps the fibrosis induced by different types of liver injury results from different fibrogenic cells. Hepatic myofibroblasts may originate from bone marrow (BM)-derived mesenchymal cells and fibrocytes, but only a small contribution of BM-derived cells to the myofibroblast population has been detected in experimental liver fibrosis (3) (4) (5) . Another potential source of myofibroblast is epithelial-to-mesenchymal transition (EMT), in which epithelial cells acquire a mesenchymal phenotype and may give rise to fully differentiated myofibroblasts. However, recent cell fate mapping studies have failed to detect any hepatic myofibroblasts originating from hepatocytes, cholangiocytes, or epithelial progenitor cells (3, (6) (7) (8) (9) (10) . Thus, the major sources of myofibroblasts in liver fibrosis are the endogenous liver mesenchymal cells, which consist of portal fibroblasts and hepatic stellate cells.
Quiescent hepatic stellate cells (qHSCs) are located in the space of Disse, store retinoids in lipid droplets, and express neural markers, such as glial fibrillary acidic protein (GFAP), synaptophisin, and nerve growth factor receptor p75 (1) . In response to injury, qHSCs down-regulate vitamin A-containing lipid droplets and neural markers, and differentiate into α-SMAexpressing myofibroblasts (1, 2) . Portal fibroblasts normally comprise a small population of the fibroblastic cells that surround the portal vein to maintain integrity of portal tract. They were first described as "mesenchymal cells not related to sinusoids," and since then have been called "periductular fibroblasts" or portal/periportal mesenchymal cells" (11) and implicated by association in the pathogenesis of cholestatic liver injury. In Significance Liver resident activated hepatic stellate cells (aHSCs), and activated portal fibroblasts (aPFs) are the major source of the fibrous scar in the liver. aPFs have been implicated in liver fibrosis caused by cholestatic liver injury, whereas fibrosis in hepatotoxic liver injury is attributed to aHSCs. However, the contribution of aPFs to cholestatic fibrosis is not well characterized because of difficulties in cell purification and the lack of identified aPF-specific markers. We have developed a novel flow cytometry-based method of aPFs purification from the nonparenchymal cell fraction of collagen-α1(I)-GFP mice and have identified potential aPF-specific markers. The goal of this study is to determine whether aPFs contribute to cholestatic liver fibrosis and identify the mechanism(s) of their activation.
response to chronic injury, portal fibroblasts may proliferate, differentiate into α-SMA-expressing myofibroblasts, and synthesize extracellular matrix (11) (12) (13) (14) .
The contribution of portal fibroblasts (PFs) to liver fibrosis of different etiologies is not well understood, mainly because of difficulties in isolating PFs and myofibroblasts. The most widely used method of PF isolation from rats is based on liver perfusion with enzymatic digestion followed by size selection (15) . Cell outgrowth from dissected bile segments is still used to isolate mouse PFs, and after 10-14 d in culture, PFs undergo progressive myofibroblastic activation (16) . The disadvantage of this technique is that it requires multiple passaging and prolong culturing (11) . A more physiological method of PF culturing in a precision-cut liver slice is designed to maintain cell-cell and cell-matrix interactions and mimic natural microenvironment of PFs, but it does not enable the study of purified PFs (17) . Therefore, only a few markers of PFs are available to identify PFs in the myofibroblast population, including gremlin, Thy1, fibulin 2, interleukin 6 (IL-6), elastin, the ecto-AT-Pase nucleoside triphosphate diphosphohydrolase-2 (NTPD2), and coffilin 1. In addition, the lack of desmin, cytoglobin, α2-macroglobulin, neural proteins (GFAP, p75, synaptophysin), and lipid droplets distinguishes PFs from HSCs (1, (17) (18) (19) (20) (21) .
Our study uses transgenic reporter mice and new flow cytometry protocols to identify the origin of myofibroblasts and quantify their numbers in two murine models of chronic liver injury (BDL and CCl 4 ). Our study demonstrates that the origin of the myofibroblasts is determined by the type of liver injury. As previously reported using other methodologies, HSCs are the major source of myofibroblasts in CCl 4 liver injury. In contrast, most of the myofibroblasts at the onset of BDL-induced liver injury originate from activated PFs (aPFs).
Results

BDL-and CCl 4 -Induced Liver Fibrosis Is Associated with Activation of
Myofibroblasts in Mice. To study activation of hepatic myofibroblasts, Col-GFP mice expressing GFP under control of collagen α1(I) promoter/enhancer (22) were subjected to BDL (20 d) or CCl 4 (1.5 mo) liver injury. Upon activation, hepatic myofibroblasts in these mice are visualized by GFP expression. Development of liver fibrosis was confirmed in Col-GFP mice by hydroxyproline content, Sirius Red staining ( Fig. 1 A and B) and correlated with increased collagen-α1(I) (fold increase 6.1 ± 0.3 and 7.6 ± 0.4 in BDL-and CCl 4 -treated vs. control mice) and α-SMA mRNA expression (fold increase 4.2 ± 0.2 and 6.1 ± 0.7 vs. control mice, respectively; Fig. 1B ). Development of liver fibrosis was also associated with activation of myofibroblasts, demonstrated by Col-GFP expression (6.5 ± 0.4% and 7.8 ± 0.5% of GFP + area in BDL-and CCl 4 -treated vs. 0.3 ± 0.03% in control mice) and α-SMA expression (Fig. 1B) . Thus, BDL and CCl 4 induced comparable levels of fibrosis and activation of myofibroblasts in the liver, sufficient to isolate GFP + myofibroblasts and determine their composition in response to two different injuries.
Isolation of Myofibroblasts. The reporter Col-GFP mice (22) have been extensively characterized and are widely used to visualize activated myofibroblasts in fibrotic liver, lungs, kidneys, and skin (3-5, 8, 23-36) . Expression of GFP in these mice closely correlates with expression of collagen type I protein in hepatic myofibroblasts but is not expressed in endothelial, epithelial, or other cell types (37) (38) (39) (Fig. 2B) . As expected, activation of hepatic myofibroblasts (GFP + cells, 100%) was observed only in injured livers (Fig. 2B) (Fig. 3A) . Using a threshold defining confident detection of gene expression, we confirmed that aPFs exhibited a myofibroblast-like phenotype, sharing mRNA expression of 8,981 genes with aHSCs. These genes included Col1a1, Col1a2, Col2a1, TIMP-1, Spp1, TGFβ-RI, and Vimentin ( Fig. 3C ) and were induced in aPFs to a level comparable to BDL-and CCl 4 -aHSCs. As expected, GFAP and Bambi mRNAs were highly expressed in qHSCs, whereas PDGF-Rb was up-regulated in aHSCs. Meanwhile, the highest expression of Acta1 was detected in CCl 4 -aHSCs (Fig. 3C ). aPFs up-regulated an additional 694 unique genes (Fig. 3A) . This set of genes was enriched in Gene Ontology biological process annotations linked to biological adhesion, response to stimulus, developmental process and cellular organization (Fig. 3B) , locomotion, focal adhesion, cell adhesion molecules, regulation of actin cytoskeleton, and were associated with the induction of the profibrogenic Wnt signaling pathway (Fig. S4) . Furthermore, aPFs up-regulated expression of IL-18R, IL-25R (Fig. 3C) , and other genes that distinguish them from aHSCs ( 
S5).
PFs Are Activated in Early BDL-Induced Liver Injury. Our data indicate that aPFs and aHSCs exhibit similar level of activation in response to BDL (20 d; Fig. 3C ). To further characterize the fibrogenic properties of aPF and aHSC, earlier time points of BDL were examined. After 5 d of BDL (Fig. 3D) , expression levels of Col1a1, aSMA, and TIMP1 mRNA were much higher in aPFs than in aHSCs, suggesting that the activation of PF precedes the activation of HSCs in BDL injury. For example, Co1la1 was 120-fold induced in aPFs over the level in qHSCs, compared with 20-fold induction in aHSCs. After 17 d of BDL (Fig. 3E) Using the whole mouse genome microarray, expression of signature genes was determined for BDL-aPFs. Expression of genes previously identified as PF-specific (underlined) was confirmed. Fold induction (compared with the highest value observed in BDL-or CCl 4 -aHSCs) is shown for each gene. Full list of genes is shown in Fig. S7 .
Functional Properties of BDL-Derived aPFs Differ from aHSCs. Previous studies have proposed differences in aPFs and aHSCs that underlie fibrogenesis of different etiologies (42) . Therefore, we assessed how aPFs and aHSCs responded to fibrogenic stimuli in vitro. As expected, the fibrogenic cytokine TGF-β1 had similar effects on aPF and aHSC (Fig. 4A) . However, aPFs were unresponsive to the known HSC agonists PDGF and NGF (demonstrated by mRNA expression of target genes CyclinD1; Bax, Bid, Bim, Bcl-2, and Bcl-xl, respectively). Despite high expression of IL-18R, treatment of aPFs with IL-18 (100 ng/mL; 8 h) did not induce expression of tested IL-18 target genes (MMP3, MMP8, and MMP13, Cox-2, iNOS, IL-6). Meanwhile, only PFs responded to the bile acid TCA, with increased Col1a1 mRNA expression (>2.2-fold induction over control aPFs), suggesting that TCA may directly mediate PF activation (Fig. 4B) . Furthermore, aPFs responded to IL-25 stimulation by induction of IL-13 [similar to IL-13 induction by IL-25-treated macrophages (43) and fibroblasts (44)]. Although IL-13 is implicated in HSC activation, and IL-13 levels are up-regulated in patients with liver cirrhosis (3, 4, 27) , the role of IL-13 in cholestatic liver injury has not been well defined. We hypothesize that IL-25-mediated IL-13 production by BDL-aPFs may stimulate activation of HSCs. To assess the effect of aPF-produced IL-13 on HSCs, qHSCs were incubated in the presence of IL-13. As we predicted (45), IL-13 increased CTCF (after 4 h) mRNA expression, and also induced up-regulation of Co1la1, aSMA, TIMP1, and mRNA (after 24 h) in HSCs (Fig. 4C) , suggesting that aPFs may locally facilitate HSC activation via production of IL-13. A more detailed analysis (Fig. 4D) 
demonstrated that stimulation of HSCs with IL-13 causes up-regulation of IL-13Ra2 expression (but not IL-13Ra1 or IL-4) and transcription of IL-13 target genes
Tenascin-C and Eotaxin (46, 47) . Because IL-13-treated HSCs did not express IL-13 or IL-6, we concluded that IL-13 directly mediated HSC activation, and this effect was associated with phosphorylation of ERK1/2 (which is completely blocked by ERK inhibitor U0126; Fig. 4E ) and activation of the p38 and Smad1/5 signaling pathways. Similar results were obtained in human primary HSCs. hIL-13 induced a dose-dependent secretion of CCL11/eotaxin (Fig. S6A) in hHSCs. In a separate experiment, hIL-13 alone (or in combination with TGF-β1) mediated an increase in IL-13Ra2, Tenascin C, Col1a1, Col3a1, fibronectin, and LoxL2 genes (Fig. S6B) . In turn, TGF-β1 and serum stimulation did not result in IL-13 secretion by hHSCs (Fig. S6C) , suggesting that aPFs may serve as a source of IL-13 in liver fibrosis.
Expression of Novel Markers Distinguishes BDL-Derived aPFs from
BDL-aHSCs and CCl 4 -aHSCs. To further distinguish aPFs from aHSCs and other myofibroblasts, we interrogated the whole mouse genome microarray to determine "signature genes" for aPFs (Table 1 ). In concordance with previous studies, we confirmed that aPFs lack expression of cytoglobin (an HSC marker), but express Thy1, elastin, Gremlin 1, Fibulin 2, and NTPD2 mRNAs (the markers that have been reported to discriminate between aPFs and aHSCs) (2, 11, (17) (18) (19) (20) (21) . However, expression of cofilin-1 (21) distinguished aPFs from CCl 4 -aHSCs, but not from BDL-aHSCs, which limits the usefulness of this marker. Furthermore, aPFs uniquely expressed calcitonin α (fold induction >48 over the highest value in BDL-aHSCs or CCl 4 -aHSCs), mesothelin (>28), uroplakin 1β (>22), basonuclin 1 (>18), asporin (>14), proteoglycan 4 (>14), glipican 3 (>12), and CD200 (>11) mRNA (Fig. S7) . Up-regulation of these genes specifically in aPFs [but not in quiescent or aHSCs, endothelial cells, Kupffer cells, and hepatocytes ( Fig. 5A and Fig. S8A ) or BDL-activated cholangiocytes (Fig. 5A and Fig. S8C )] was confirmed by RT-PCR and immunohistochemistry, suggesting that these genes may serve as potential novel markers of aPFs. Some of these genes (including basonuclin 1, glycoprotein m6a, uroplakin 3b and 1b, mesothelin, IL-18R, calcitonin-related peptides, and vitrin) were reported as signature genes of murine hepatic mesothelial (48) and epicardial cells (49) (Fig. S7) , supporting the theory that PFs originate from mesothelial cells (50, 51) .
The role of most of these genes in liver fibrosis has not been evaluated, with the exception of calcitonin α and mesothelin. Calcitonin α, a calcium metabolism regulating hormone, was implicated in pathogenesis of cholestatic injury, and mice devoid of calcitonin α are more resistant to BDL-induced liver fibrosis (52) . In turn, mesothelin, a glycosylphosphatidylinositol-linked glycoprotein, is expressed in hepatic mesothelial cells and malignant mesotheliomas (53) and mediates intracellular adhesion and metastatic spread (54) . Mesothelin knockout mice are viable and exhibit no obvious abnormalities (55) . Expression of mesothelin was detected only in isolated aPFs but not in other cellular fractions (Fig. 5A) .
Expression of Mesothelin Is Up-Regulated in aPFs in Response to
Injury. We examined the expression of mesothelin in isolated aPFs and aHSCs. Unlike GFP +
GFAP
+ aHSCs, GFP + aPFs expressed mesothelin (97 ± 1.7%). Mesothelin + aPFs coexpressed elastin (detected with TE-7 Ab) and Thy1, and immunostaining with mesothelin colocalized with Elastin 
Thy1
+ aPFs ( Fig. 5B and Fig. S8B ). Next, expression of mesothelin was evaluated in livers of BDL-and CCl 4 -injured mice ( Fig. 5C and Fig. S8B ). In concordance with our previous findings, very few mesothelin + cells were detected in CCl 4 -injured livers. In contrast, mesothelin was highly expressed in livers from BDLinjured mice, with an expression pattern similar to the other PF markers Thy1 and elastin (Fig. S8 B and C) . In support of our findings, expression of mesothelin mRNA was also detected in laser capture microdissected portal areas from BDL (20 d)-treated mice but not from CCl 4 -treated mice (Fig. 5D) . In addition, mesothelin was not expressed in sham-operated mice, suggesting that mesothelin identifies the aPF phenotype.
Discussion
Our study was designed to determine the origin of hepatic myofibroblasts activated in response to chronic injury of two different etiologies. We demonstrate that hepatotoxic (CCl 4 ) and cholestatic (BDL) liver injuries activate distinct subsets of fibrogenic myofibroblasts. Thus, CCl 4 activates preferentially aHSCs, whereas BDL initially preferentially aPFs. We developed a reliable method of isolation and quantification of hepatic myofibroblast fractions by using flow cytometry. Based on the distinctive expression of Vitamin A and GFAP in HSCs and Thy1 and elastin in PFs, this study establishes cell sorting as a robust method to purify distinct populations of myofibroblasts in mice, providing a nonbiased approach to purify and characterize all myofibroblasts. By demonstrating that HSCs are the major source of myofibroblasts in hepatotoxic liver injury (CCl 4 ), we confirmed the previous cell fate mapping studies that used GFAP-Cre (56, 57), PDGFRb-Cre (58), and Lrat-Cre (59) .
In contrast to CCl 4 -induced injury, our study demonstrates that PFs rapidly activate at the onset of cholestatic injury and upregulate fibrogenic genes. Furthermore, early activation of PFs during BDL injury may affect HSCs, and BDL-aHSCs exhibit more similarity to aPFs than to CCl 4 -aHSCs. Gene expression profiling demonstrated novel signature genes for aPFs. According to cell fate mapping, PFs originate from the mesothelium (51, 60) , and our data suggest that aPFs share similarity in signature gene expression with other cells of mesothelial origin. One of these genes, mesothelin, is highly induced specifically in aPFs in response to BDL injury, suggesting that mesothelin may become a new target for antifibrotic therapy.
aHSCs and aPFs Are the Major Source of Myofibroblasts in Fibrotic
Liver. Although vitamin A-rich lipid droplets are a distinctive characteristic of HSCs, activation results in a decrease in these droplets (1) . However, in vivo aHSCs do not lose their vitamin A droplets completely, and vitamin A-induced buoyancy has become a standard way to purify quiescent and aHSCs in vivo, as confirmed by gene expression profiling (25, 41) . Our current study provides additional proof that vitamin A is a reliable marker for identification, quantification, and purification of aHSCs, making flow cytometry using vitamin A autofluorescence as the method of choice to purify aHSCs from myofibroblasts of other origins. Flow cytometry enables identification of hepatic myofibroblasts and isolation of distinct subsets of myofibroblasts (HSCs and PFs) with high purity from the same mouse liver.
Using collagen-GFP reporter mice, we demonstrate that the total population of GFP + myofibroblasts isolated in the nonparenchymal fraction consists of two major populations: Vit.A + cells that exhibit specific morphology. In turn, Vit.A − aPFs lacked GFAP or Desmin expression, but were characterized by expression of Thy1 and Elastin, and a more round-shaped morphology. Collectively, HSCs and PFs contribute to more than 94% of GFP + myofibroblasts. This type of analysis should now be extended to other experimental models of liver fibrosis, such as alcohol-induced liver disease and nonalcoholic steatohepatitis.
aHSCs and aPFs Contribute Differently to Liver Fibrosis of Different
Etiologies. Although the role of aPFs in the development of portal fibrosis has been discussed (42, 61), our study is the first to our knowledge to quantify the myofibroblast populations over a time course. Consistent with previous studies (62, 63) , we demonstrate that aPFs play an important role at early stages of BDL-induced liver fibrosis (13) by contributing >70% of myofibroblasts. Moreover, even at later stages (BDL, 17-20 d), aPFs contribute ∼50% of myofibroblasts and exhibit a more activated phenotype than aHSCs. Thus, the composition of myofibroblasts varies depending on the etiology and time course of liver injury and fibrosis.
Cholestatic Injury Induces Predominant Activation of aPFs. The mechanism of fibrogenesis differs in CCl 4 and BDL models of liver injury. Treatment with CCl 4 is hepatotoxic, causing necrosis of hepatocytes and inflammation in the pericentrolobular area. However, BDL induces obstruction of bile flow with increased biliary pressure, moderate inflammation, and cytokine secretion by biliary epithelial cells (64) . Diffusion (accumulation) of free bile acids may trigger ductular reaction (hyperplastic response of bile duct epithelial cells), resulting in activation of cholangiocytes and portal fibroblasts. The mechanism of PF activation is poorly understood. Here, we propose that TCA bile acid can directly activate PFs (but not HSCs) into myofibroblasts, and this effect may rely on TCA-induced induced cytotoxicity, because PFs have been reported to lack the bile acid receptors FXR (farnesoid X receptor) and TGR5 (the membrane G protein-coupled Fig. 4 . Functional properties of aPFs and aHSCs. (A) Response to cytokines was compared in BDL-aPFs and CCl 4 -aHSCs. Both aHSCs and aPFs responded to TGF-β1 (10 ng/mL). aHSCs, but not aPFs, responded to PDGF (100 pg/mL) and NGF (100 ng/mL). The data are fold induction compared with untreated aPFs (or aHSCs), P < 0.01. (B) BDL-aPFs (but not BDL-aHSCs or CCl 4 -aHSCs) responded to bile acid taurocholic acid (TCA; 1,200 nmol/mL) by up-regulation of Col1a1, and to IL-25 (100 ng/mL) by IL-13 secretion, P < 0.05. Stimulation of aPFs with Tauro-ursodeoxycholate (TUDCA; 25 nmol/mL), deoxycholic acid (DCA; 0.1 nmol/mL), taurochenodeoxycholate (TCDCA; 60 nmol/mL), Tauro b-muricholate (TbMCA; 2,000 nmol/mL), and cholic acid (CA; 20 nmol/mL) did not result in Col1a1 induction. The data are fold induction compared with untreated aPFs (or aHSCs), *P < 0.05. (C) The effect of IL-13 on HSC activation was evaluated. qHSCs were incubated with IL-13 (100 ng/mL) for 4 h and 24 h. Gene expression was evaluated by RT-PCR, *P < 0.01; **P < 0.02; ns, nonsignificant. The data (A-C) represent three independent experiments. For each experiment, the cells were isolated from three mice. (D) IL-13 signaling in mouse HSCs: IL-13-stimulated HSCs (100 ng/mL, 6 h) up-regulate IL-13Rα2, tenascin C, and eotaxin, but do not express IL-13 or IL-6, as shown by RT-PCR. (E) IL-13 signaling in HSCs (2 h) causes phosphorylation of ERK1/2 (which is blocked by ERK inhibitor U0126, 10 μM), p38, and Smad1/5, as shown by Western blot. TGF-β1-stimulated HSCs served as a control.
receptor) (65, 66) . TCA-induced activation of PFs appears to be specific, and stimulation with other bile acids (TUDCA, DCA, TCDCA, TbMCA, CA) did not induce fibrogenic gene expression in PFs. However, unresponsiveness of PFs to tested bile acids may result from already high activation of isolated PFs (5 d after BDL), the lack of corresponding receptors (65), or poor experimental conditions (67) . In addition, individual bile acids may produce other effects on PFs, such as cellular proliferation and cytokine secretion (17) , which were not evaluated in this study. Furthermore, our in vitro conditions may not mimic the complex liver microenvironment required for bile acid stimulation of PFs (17) . Alternatively, bile acids may indirectly induce PF activation by affecting cholangiocytes (68) or hepatocytes (65) that, in turn, may facilitate selective aPF activation via cell-cell signaling or cytokine secretion (64) . In addition, specific factors produced by activated cholangiocytes may presensitize PFs for bile acid stimulation (69) . Another characteristic feature of aPFs is expression of IL-25R. Up-regulation of proinflammatory IL-17A, IL-25, IL-22, and IL-6 in the serum and in the liver accompany development of BDL-induced liver fibrosis (28) . Therefore, it is not surprising that IL-25 may stimulate aPFs. Similar to other cell types, IL-25 induced secretion of IL-13 by aPFs, but did not further their activation. IL-13 has been implicated in pathogenesis of Schistosoma mansoni infection-induced liver fibrosis (70) , and recently IL-13 was shown to directly stimulate HSCs to produce CTGF and subsequently upegulate fibrogenic genes in response to nonparasite liver injury (71) . Therefore, we hypothesized that following BDL, IL-25-stimulated aPFs secrete IL-13, which facilitates HSC activation (via induction of IL-13Ra2, Col1a1, Eotaxin, Tenascin-C, fibronection, and phosphorylation of ERK1/ 2). Supporting this notion, bone marrow transplantation in Abcb4 −/− mice lessened hepatic fibrosis via Th1 responses, but did not alter the level of IL-13 production (72), suggesting there must be an endogenous source of IL-13 in these mice. Further studies are required to determine the mechanism of HSC activation in response to cholestatic liver injury. 
Elastin
− aHSCs. Using gene expression profiling of in vivo aHSCs and aPFs, we have identified that mesothelin, calcitonin α, uroplakin 1β, basonclin 1, asporin, IL-18R1, and IL-25R may serve as additional useful markers to distinguish aPFs from aHSCs and myofibroblasts of other origins. We determined that these genes are highly expressed in portal fibroblasts but not in other cell types in fibrotic liver. (1.5 mo)-treated mice (n = 3 per group), cells were analyzed by RT-PCR for expression of aPF-and aHSC-specific markers. Mesothelin, elastin, and Thy1 were highly expressed in myofibroblasts obtained from periportal area of BDL liver. Desmin was expressed at high levels in CCl 4 -treated liver. Unlike desmin, mesothelin was not expressed in CCl 4 -treated periportal area. The data (from three independent experiments) are mRNA fold induction compared with periportal area of sham mice, *P < 0.01; **P < 0.05; ns, nonsignificant.
Interestingly, aPFs express mesothelin, calcitonin α, uroplakin 1β, basonclin 1, asporin, and IL-18R1 genes. The hepatic mesothelium is the source of HSCs and PFs during development (51, 60) . Previous studies have demonstrated that the genes mentioned above and other genes [e.g., glycoprotein m6a, mesothelin, Uroplakin 1β and 3 β, Cyp2s1, mucin 16, crystalline, Prss12, Slipi, Caveolin, Dermokin, Calcitonin-related peptide, vanin, cytokeratin 7, Slc9a3r1, and Slc39a8 (metal ion transporter)], Igfbp6, see Fig. S6 ) are expressed in hepatic mesothelium (48) . Furthermore, the gene expression profiles of epicardium isolated from adult mouse infarction-injured hearts identified the same genes among epicardium-specific signature genes, and for the first time, to our knowledge, implicated these genes (alone or in combination) in wound healing (49) . Morphological studies have suggested that septum transversum mesenchyme (STM) is the source of hepatic mesenchymal cells (HSCs and perivascular mesenchymal cells) (73) and cardiac mesoderm [that gives rise to epicardium (74) ]. Therefore, a common origin of hepatic mesothelium and epicardium may explain the similarity of gene expression profile of these tissues. During development, hepatic mesothelium undergoes an epithelial-to-mesenchymal (EMT) transition to produce PFs and HSCs. Furthermore, the expression of WT1, a mesothelial-specific factor (60) , is expressed in aPFs (vs. aHSCs; Fig. S6 ). Because both hepatic mesothelium and epicardium can contribute to myofibroblasts in their respective organs, the contribution of the aforementioned genes to repair and fibrosis should be addressed.
Mesothelin is a glycosyl phosphatidylinositol (GPI)-anchored membrane glycoprotein that is expressed in normal mesothelial cells. It is also highly expressed in several species of malignant tumors, such as mesothelioma as well as ovarian and pancreatic cancers (75) (76) (77) . We determined that mesothelin (Msln)-deficient mice are less susceptible to liver fibrosis compared with the wild-type mice. Previous studies have implicated mesothelin in mediation of cellular interaction and metastatic dissemination. Because of a strong induction in different types of cancer, mesothelin is considered as a tumor-associated antigen, which serves as a prognostic marker of disease progression, and became a therapeutic target for anti-cancer therapy. Here we demonstrate that mesothelin is highly expressed in aPFs in response to BDL, so that mesothelin may serve as a novel marker of aPFs and a potential target for antifibrotic therapy.
Materials and Methods
Mice and Liver Injury. Collagen α1(I)-GFP mice (22) and wild-type littermates were used at 8 wk of age, in C57BL/6 background. Liver injury was induced in mice by CCl 4 (1:4 dilution in corn oil, 60 μL × 14 injections; ref. 41) or ligation of the common bile duct (20 d) (41) . Mice were maintained under specific pathogen free conditions at the animal facilities of University of California, San Diego (protocol S07088 approved by Institutional Animal Care and Use Committee).
Isolation of Nonparenchymal Fraction. Livers were perfused and digested by using the pronase/collagenase method (41) , and cells were centrifuged to pellet the hepatocytes. The remaining nonparenchymal cell fraction [containing hepatic myofibroblasts (HSCs, portal fibroblasts, and others) hepatic stellate cells by using RNeasy columns (Qiagen). Gene expression levels were calculated after normalization to the standard housekeeping gene 18S by using the ΔΔ CT method as described by the manufacturer (Invitrogen) and expressed as relative mRNA levels compared with control. The results are represented as mean ± SEM, P < 0.0001.
Laser Capture Microdissection and RNA Extraction. Livers from sham-, CCl 4 -and BDL-injured mice were snap-frozen in FSC 22 Frozen Section Media (Leica Microsystems) and stored at −80°C. Transverse sections (10 μm) were cut with a cryostat at −20°C. Cryosections were mounted on membranecoated slides. A Leica LMD7000 system (Leica Microsystems) was used to cut periportal or centrilobular area on sections. Microdissected sections were collected in the lid of a 0.5-mL microtube containing RLT buffer from the RNeasy (Qiagen). Total RNA was extracted by using the same kit and following the manufacturer's instructions.
